期刊文献+

冠脉复杂病变PCI术后伊诺肝素抗凝对临床事件的影响 被引量:6

Effect of enoxaparin on clinical events in complicated coronary lesions after percutaneous coronary intervention
下载PDF
导出
摘要 目的 探讨复杂病变经皮冠状动脉介入治疗(PCI)术后伊诺肝素抗凝对临床事件的影响。方法 入选复杂冠脉病变(B2、C型病变)行PCI术后无特殊并发症的患者288例,随机分为伊诺肝素抗凝组(n=145)与非抗凝组(n=143),记录住院期间出血事件发生率及住院时间,并分别在住院期间及术后1个月、1年随访时记录主要心血管不良事件(MACEs)。结果 伊诺肝素抗凝组与非抗凝组住院期间、术后1个月、1年时MACEs的发生率差异无统计学意义(住院期间:2.1%vs1.4%,P〉0.05;1个月时:2.8%vs 2.8%,P〉0.05;1年时:5.5%vs 6.3%,P=0.780)。两组间MACEs累计发生率差异无统计学意义(HR=0.875,95%CI 0.337~2.273,P=0.79)。抗凝组与非抗凝组住院期间主要出血发生率(4.8%vs 2.8%,P=0.369)差异无统计学意义,但抗凝组小出血发生率较高(26.2%vs 16.1%,P=0.036)。抗凝组的平均住院天数多于非抗凝组[(6.04±1.64)d vs(5.43±1.54)d,P=0.001]。结论 复杂病变PCI术后非抗凝治疗组不仅不增加心血管事件,而且减少出血事件、缩短住院天数。提示即使是复杂冠脉病变,PCI术后若无特殊并发症可无需肝素抗凝治疗。 Objective To explore the influence of enoxaparin on clinical events in complicated coronary lesions after percutaneous coronary intervention(PCI).Methods Totally 288 patients with complicated coronary lesions(type B2 and type C),who had no notable complications following PCI,were recruited in the present study.The patients were randomly assigned to receive either enoxaparin or not.Patients were assessed for major adverse cardiac events(MACEs)during hospitalization and at 1and 12 months after PCI.Results There were no significant differences in the frequency of MACEs between the two groups during hospitalization(2.1% vs 1.4%,P〉0.05),at 1 month(2.8% vs 2.8%,P〉0.05)or 12 months post-PCI(5.5% vs 6.3%,P=0.780).The cumulative incidence rates of MACEs were not significantly different between the two groups(HR=0.875,95%CI 0.337-2.273;P=0.79).The two groups had comparable rates of major bleeding(4.8% vs2.8%,P=0.369),but that of the minor bleeding was significantly higher in the anticoagulation group(26.2% vs 16.1%,P=0.036).The average hospital stay in the anticoagulation group were significantly longer than that in the non-anticoagulation group([6.04±1.64]d vs [5.43±1.54]d,P=0.001).Conclusion MACEs after PCI is not increased in patients with complicated coronary lesions receiving no anticoagulation compared with those receiving,with less minor bleeding and shorter hospital stay,suggesting that for the patients with complicated coronary lesions,routine anticoagulation therapy is not necessary after PCI without procedure complications.
出处 《第二军医大学学报》 CAS CSCD 北大核心 2015年第10期1074-1079,共6页 Academic Journal of Second Military Medical University
基金 上海市科委科研计划项目(10411954900)~~
关键词 经皮冠状动脉介入治疗 复杂病变 伊诺肝素 主要心血管不良事件 出血 percutaneous coronary intervention complicated lesions enoxaparin major adverse cardiac events bleeding
  • 相关文献

参考文献28

  • 1Swanson N, Hogrefe K, Stephens Lloyd A, Gershlick A. Current perspectives on British use of adjunctive therapies during coronary interventions[J]. Int J Cardiol, 2001,79(2-3):119-127.
  • 2Gregorini L, Marco J, Fajadet J, Bernies M, Cassagneau B, Brunel P, et al. Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures[J]. J Am Coll Cardiol, 1997, 29: 13-20.
  • 3Wright R S, Anderson J L, Adams C D, Bridges C R, Casey D E Jr, Ettinger S M, et al. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons[J]. J Am Coll Cardiol, 2011, 57: 1920-1959.
  • 4Jneid H, Anderson J L, Wright R S, Adams C D, Bridges C R, Casey D E Jr, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol, 2012, 60: 645-681.
  • 5中华医学会心血管病学分会,中华心血管病杂志编辑委员会.经皮冠状动脉介入治疗指南(2009)[J].中华心血管病杂志,2009,37:4-25.
  • 6Feit F, Voeltz M D, Attubato M J, Lincoff A M, Chew D P, Bittl J A, et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial[J]. Am J Cardiol, 2007, 100: 1364-1369.
  • 7Manoukian S V, Feit F, Mehran R, Voeltz M D, Ebrahimi R, Hamon M, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial[J]. J Am Coll Cardiol, 2007, 49: 1362-1368.
  • 8Kinnaird T D, Stabile E, Mintz G S, Lee C W, Canos D A, Gevorkian N, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions[J]. Am J Cardiol, 2003, 92: 930-935.
  • 9Eikelboom J W, Mehta S R, Anand S S, Xie C, Fox K A, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes[J]. Circulation, 2006, 114: 774-782.
  • 10Rao S V, O'Grady K, Pieper K S, Granger C B, Newby L K, Van de Werf F, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes[J]. Am J Cardiol, 2005, 96:1200-1206.

共引文献4

同被引文献50

引证文献6

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部